SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (975)4/13/2000 12:36:00 PM
From: Ron  Read Replies (1) of 1386
 
Dr. Tracy,
I know in your post #975 you wrote that the FDA has made it clear to Pharmos that they will not allow ICP to be the primary endpoint in phase 3 for HU-211.

My question is why wouldn't the FDA allow ICP as an endpoint if the drug improves the condition of TBI victims by lowering ICP without lowering the blood pressure. I believe I have read somewhere that lowering the ICP could prevent the devastation caused by the "cascade" effect.

Thank you.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News